WhatPeptide

TB-500

A synthetic fragment associated with thymosin beta-4 signaling that is studied for migration, remodeling, and tissue repair in preclinical injury models.

Animal studies only FDA Category 2 Healing & Recovery

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

FDA Category 2 — compounding availability may be limited.

Half-life

Estimated 2-6 hours (active fragment uncertain)

Dosage range

2-5 mg weekly divided doses (research context)

Administration

Subcutaneous injection

Research level

Animal only

How TB-500 works

TB-500 is linked to actin-binding and cellular migration pathways associated with tissue remodeling. Thymosin beta-4 biology also intersects with angiogenesis and anti-inflammatory signaling in animal data. Human performance and rehabilitation evidence remains sparse.

Also known as: Thymosin Beta-4 fragment, Tβ4

Research relevance

Recovery & Healing
Moderate relevance 60
Injury Rehab
Moderate relevance 60
Immune Support
Some relevance 35
Anti-Aging & Longevity
Some relevance 30
Hair & Skin
Some relevance 30
Muscle Growth
Some relevance 20
Gut Health
Some relevance 20

Side effects & safety

Injection-site discomfort Fatigue Headache

Contraindications

Pregnancy/breastfeeding
Use in active cancer should be clinician-supervised

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is TB-500? +
A synthetic fragment associated with thymosin beta-4 signaling that is studied for migration, remodeling, and tissue repair in preclinical injury models. Its mechanism of action is based primarily on animal and in-vitro studies.
What is TB-500 researched for? +
TB-500 has the strongest research relevance for Recovery & Healing, Injury Rehab, Immune Support. Evidence is based primarily on animal and in-vitro studies.
What are the side effects of TB-500? +
Reported side effects include Injection-site discomfort, Fatigue, Headache. Key contraindications: Pregnancy/breastfeeding; Use in active cancer should be clinician-supervised.
Is TB-500 FDA approved? +
TB-500 is classified as FDA Category 2, meaning compounding availability may be limited.
How is TB-500 administered? +
TB-500 is typically administered via subcutaneous route. Researched dosage range: 2-5 mg weekly divided doses (research context). Half-life: Estimated 2-6 hours (active fragment uncertain).

Explore similar peptides

ARA-290

Preliminary evidence

Healing & Recovery

ARA-290 is a non-hematopoietic erythropoietin-derived peptide engineered to activate the innate repair receptor without stimulating red blood cell production, studied for neuropathic pain and tissue repair. Clinical trials have explored its utility in sarcoidosis-related nerve damage and diabetic neuropathy.

BPC-157

Animal studies only

Healing & Recovery

A pentadecapeptide derived from human gastric juice that has demonstrated tissue-protective and regenerative properties across multiple animal models.

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

Ipamorelin

Moderate evidence

Growth Hormone Releasing Peptide

A selective ghrelin-receptor agonist studied for stimulating GH release with less prolactin/cortisol impact than older GHRPs. Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.